- Home
- NETD vs IRWD Comparison
NETD vs IRWD Comparison
Compare NETD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- IRWD
- Stock Information
- Founded
- NETD 2023
- IRWD 1998
- Country
- NETD United States
- IRWD United States
- Employees
- NETD N/A
- IRWD N/A
- Industry
- NETD
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- NETD
- IRWD Health Care
- Exchange
- NETD Nasdaq
- IRWD Nasdaq
- Market Cap
- NETD 242.3M
- IRWD 251.8M
- IPO Year
- NETD 2023
- IRWD 2010
- Fundamental
- Price
- NETD $11.55
- IRWD $3.86
- Analyst Decision
- NETD
- IRWD Buy
- Analyst Count
- NETD 0
- IRWD 5
- Target Price
- NETD N/A
- IRWD $5.34
- AVG Volume (30 Days)
- NETD 227.7K
- IRWD 3.8M
- Earning Date
- NETD 01-01-0001
- IRWD 11-10-2025
- Dividend Yield
- NETD N/A
- IRWD N/A
- EPS Growth
- NETD N/A
- IRWD N/A
- EPS
- NETD 0.07
- IRWD 0.18
- Revenue
- NETD N/A
- IRWD $338,987,000.00
- Revenue This Year
- NETD N/A
- IRWD N/A
- Revenue Next Year
- NETD N/A
- IRWD N/A
- P/E Ratio
- NETD $170.65
- IRWD $21.88
- Revenue Growth
- NETD N/A
- IRWD N/A
- 52 Week Low
- NETD $10.72
- IRWD $0.53
- 52 Week High
- NETD $11.75
- IRWD $5.13
- Technical
- Relative Strength Index (RSI)
- NETD 60.39
- IRWD 78.44
- Support Level
- NETD $11.30
- IRWD $3.07
- Resistance Level
- NETD $11.75
- IRWD $3.40
- Average True Range (ATR)
- NETD 0.09
- IRWD 0.39
- MACD
- NETD 0.02
- IRWD 0.05
- Stochastic Oscillator
- NETD 48.89
- IRWD 97.56
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.